Mahendra Deonarain
Chief Executive Officer Antikor
Seminars
Wednesday 18th March 2026
Panel Discussion: Comparing the Benefits & Limitations of a ‘Fast In, Fast Out’ Approach
2:00 pm
- Discussing the impact of small format conjugates on PK profiles
- Discussing how linker selection can impact the overall performance of small format conjugates
- Highlighting their potential vs their pitfalls for tumor types which are resistant to ADCs
Wednesday 18th March 2026
Improving Delivery Efficiency & Unlocking New Indications Through Antibody-Fragment Conjugates
1:30 pm
- Antikor’s platform for recombinant antibody fragments optimized for developability and payload bioconjugation
- Process for Antibody Fragment Drug Conjugate (FDC) discovery, tailoring the linker-payload
- Update on ANT-045, our lead FDC program for cMET-expressing solid tumours
- An insight into Antikor’s follow up projects
